Herantis Pharma Plc, a company working on therapies for Parkinson’s disease, released its 1H 2025 report, showing progress in advancing HER-096 through Phase 1b study. The company reported positive pharmacokinetic data and is preparing for the Phase 2 study. A webcast will be held on August 21st at 10:00 EEST to discuss the report. In business highlights, Herantis completed a directed share issue in February, raising EUR 5.2 million. Key figures show financial data for the period. The company expects to present topline data for HER-096 by mid-October and continue partnership discussions for Phase 2 study.

Source: www.herantis.com

For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: [email protected]

Herantis Pharma is developing disease-modifying therapies for Parkinson’s disease. Their lead product, HER-096, is in Phase 1b trial for safety and tolerability in Parkinson’s patients. The company is listed on Nasdaq First North Growth Market Finland. Forward-looking statements in the report discuss future expectations and potential risks.

Source: www.herantis.com

Read more at GlobeNewswire: Herantis Pharma releases 1H 2025 report today